Loading...
•
Dec 31, 2023
Sera Prognostics Q4 2023 Earnings Report
Reported fourth quarter and full year 2023 financial results.
Key Takeaways
Sera Prognostics reported fourth quarter 2023 revenue of $41,000, a decrease compared to $65,000 for the same period in 2022. The net loss for the quarter was $7.9 million, compared to $9.7 million for the same quarter a year ago.
DSMB recommended stopping enrollment in the PRIME study due to efficacy.
Preparing manuscript submission to premier medical publications for the PRIME study.
Making progress in development of product pipeline and PreTRM® sample collection and assay enhancements.
Engaged in focused commercial activities ahead of PRIME data to build toward greater PreTRM® test adoption expectations in 2024-2025.
Sera Prognostics
Sera Prognostics
Forward Guidance
Sera is looking forward to an exciting year of developments, including publication of their PRIME study results while executing on commercial expansion and plans to establish direct relationships with expectant mothers, expecting these activities and advancements in their product pipeline to complement what they believe is their leading position in the area of maternal and neonatal health and pave the way for a future inflection in revenue growth.
Positive Outlook
- Publication of PRIME study results in 2024.
- Commercial expansion.
- Plans to establish direct relationships with expectant mothers.
- Advancements in product pipeline.
- Potential future inflection in revenue growth.
Challenges Ahead
- Net losses.
- Need to generate cash.
- Potential need to raise more capital.
- Revenues from the PreTRM Test representing substantially all Company revenues to date.
- The need for broad scientific and market acceptance of the PreTRM Test.